OGN
Organon & Co.

1,412
Mkt Cap
$1.57B
Volume
6.34M
52W High
$15.85
52W Low
$6.02
PE Ratio
8.41
OGN Fundamentals
Price
$6.03
Prev Close
$6.27
Open
$6.29
50D MA
$7.72
Beta
0.89
Avg. Volume
4.86M
EPS (Annual)
$0.7171
P/B
2.09
Rev/Employee
$621,600.00
$10,095.68
Loading...
Loading...
News
all
press releases
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know
Organon (OGN) closed at $6.23 in the latest trading session, marking a -2.5% move from the prior day.
Zacks·4d ago
News Placeholder
More News
News Placeholder
Organon & Co. (NYSE:OGN) Hits New 12-Month Low - Here's Why
Organon & Co. (NYSE:OGN) Reaches New 1-Year Low - Here's Why...
MarketBeat·5d ago
News Placeholder
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks·6d ago
News Placeholder
Gotham Asset Management LLC Buys 1,007,691 Shares of Organon & Co. $OGN
Gotham Asset Management LLC grew its stake in Organon & Co. (NYSE:OGN - Free Report) by 37.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission...
MarketBeat·7d ago
News Placeholder
Royce & Associates LP Trims Position in Organon & Co. $OGN
Royce & Associates LP lessened its stake in shares of Organon & Co. (NYSE:OGN - Free Report) by 92.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional...
MarketBeat·16d ago
News Placeholder
Organon & Co. (NYSE:OGN) Short Interest Up 21.9% in February
Organon & Co. (NYSE:OGN - Get Free Report) was the recipient of a significant increase in short interest in February. As of February 13th, there was short interest totaling 17,545,543 shares, an...
MarketBeat·19d ago
News Placeholder
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis
Organon reports Phase 3 data showing VTAMA improved sleep in children as young as two with atopic dermatitis, reinforcing its dermatology push.
Zacks·21d ago
News Placeholder
Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages
Shares of Organon & Co. (NYSE:OGN - Get Free Report) have earned a consensus rating of "Reduce" from the seven research firms that are covering the company, MarketBeat.com reports. Five research...
MarketBeat·21d ago
News Placeholder
New Analysis of Organons VTAMA (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from...
Business Wire·24d ago
News Placeholder
Vanguard Group Inc. Has $383.72 Million Position in Organon & Co. $OGN
Vanguard Group Inc. raised its holdings in Organon & Co. (NYSE:OGN - Free Report) by 11.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange...
MarketBeat·24d ago
<
1
2
...
>

Latest OGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.